BEIJING – Shenzhen-listed Chinese firm Nanjing Hicin Pharmaceutical Co. Ltd. has in-licensed an isocitrate dehydrogenase (IDH) inhibitor known as I111b from Italian oncology specialist Nerviano Medical Sciences Srl (NMS) to develop and commercialize the drug globally for patients with acute myeloid leukemia (AML).